Loading clinical trials...
Loading clinical trials...
Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy Using Autologous Mesenchymal Stem Cell
This is a multicenter, long term safety and efficacy follow up study for with insulin dependent diabetes 2 type who have been treated with ex vivo gene therapy product in Ukraine Association of Biobank bio-sponsored clinical studies. After completing the parent clinical study (2 years),eligible subjects will be followed for an additional 8 years for total 10 years post-drugproduct infusion. No investigation drug product will be administered in the study
Age
All ages
Sex
ALL
Healthy Volunteers
No
Institute of Bio-Stem Cell Rehabilitation
Kharkiv, Ukraine
Start Date
October 15, 2020
Primary Completion Date
September 1, 2021
Completion Date
October 10, 2030
Last Updated
October 15, 2021
91
ACTUAL participants
Long term follow up
OTHER
Lead Sponsor
Ukraine Association of Biobank
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03478215